background
banner

TEVAGRASTIM 48 MIU/0.8 ml Price

Active Substance: Filgrastim .

614
UAD , based on 7541 reviews.
View Drug details

Overview

Welcome to Dwaey, specifically on TEVAGRASTIM 48 MIU/0.8 ml page.
This medicine contains an important and useful components, as it consists of
Filgrastim is available in the market in concentration

Name

Filgrastim

Precaution

Filgrastim should not be administered within 24 hours before and after chemotherapy. Premalignant or malignant myeloid condition; sickle-cell disease; osteoporotic bone disease; withdraw treatment if there are signs of pulmonary infiltrates. Fluid retention or heart failure. Monitor CBC and platelet count during therapy. Monitor bone density in patients with osteoporosis (long-term treatment). Regular morphological and cytogenic bone-marrow examinations in severe congenital neutropenia. Pregnancy and lactation. Lactation: excretion in milk unknown; use with caution

Indication

Myelosuppressive chemotherapy, Acute Myeloid Leukemia receiving induction or consolidation chemotherapy, Peripheral blood progenitor cell collection and therapy, Severe Neutropenia, Bone marrow transplantation, HIV infection.

Contra indication

Hypersensitivity to E. coli derived proteins, Filgrastim or any component of the product. Myeloid malignancies. Not to be used within 24 hr of cytotoxic chemotherapy admin due to the sensitivity of rapidly dividing myeloid cells. Severe congenital neutropaenia (Kostman's syndrome) with abnormal cytogenetics.

Side Effect

>10% Nausea (57%),Vomiting (57%),Bone pain (22%-33%),Alopecia (18%),Diarrhea (14%),Fever (12%),Fatigue (11%) 1-10% Headache,Anorexia,Chest pain,Cough,Dyspnea,Constipation,Stomatitis,Sore throat,Rash Frequency Not Defined Elevated uric acid,Elevated lactate dehydrogenase,Elevated alkaline phosphatase Potentially Fatal: Pulmonary infiltrates leading to resp failure or acute resp distress syndrome.

Pregnancy Category ID

3

Mode of Action

Filgrastim is a granulocyte-colony stimulating factor which binds to cell surface receptors on haemetopoietic cells thus stimulating the development of granulocytes to increase their migration and cytotoxicity.

Interaction

Myelosuppressive antineoplastic agents. Drugs which may potentiate the release of neutrophils e.g. lithium.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration

banner

Report Error

Please feel welcome to contact us with any price or medical error. Our team will receive any reports.